Free tool
FAERS Monitor: Margenza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761150 or its brand name (Margenza, Margetuximab-Cmkb). Reports on generic versions are filed under their own applications.
Reports
27
Serious
14
52% of reports
Hospitalization
3
Death reported
9
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death5
- disease progression5
- chills3
- infusion related reaction2
- abdominal pain1
- alopecia1
- anaphylactic reaction1
- asthenia1
- blood pressure decreased1
- cardiac disorder1
- constipation1
- diarrhoea1
- drug ineffective1
- drug intolerance1
- fatigue1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 8 |
| 2022 | 12 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,132 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease progressionSignal | 5 | 32.9 | 14.9 | 125 |
| infusion related reaction | 2 | 23.5 | 6.2 | 24 |
| chillsSignal | 3 | 19.9 | 6.9 | 37 |
| anaphylactic reaction | 1 | 14.1 | 2.1 | 3 |
| blood pressure decreased | 1 | 11.7 | 1.7 | 2 |
| cardiac disorder | 1 | 8.3 | 1.2 | 1 |
| drug intolerance | 1 | 8.1 | 1.2 | 1 |
| deathSignal | 5 | 4.5 | 2.0 | 11 |
| alopecia | 1 | 4.0 | 0.6 | 0 |
| constipation | 1 | 3.6 | 0.5 | 0 |
| abdominal pain | 1 | 3.3 | 0.5 | 0 |
| asthenia | 1 | 2.1 | 0.3 | 0 |
| diarrhoea | 1 | 1.2 | 0.2 | 0 |
| fatigue | 1 | 1.0 | 0.1 | 0 |
| drug ineffective | 1 | 0.6 | 0.1 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.